Skip to content

Nanoparticle infusion works against clogged arteries

Artery inflammation is one of the main causes of cardiovascular disease – the No. 1 cause of death in the U.S. This inflammation is accompanied by the formation of dangerous plaques in the arteries. Advanced treatments are needed to combat this inflammation in patients. Researchers at Michigan State University have tested a new nanoparticle nanotherapy infusion that specifically targets inflammation and activates the immune system to support the removal of plaque in the arteries. Smith and his team, including lead authors Yapei Zhang and Manisha Kumari, created nanoparticles – materials thinner than a human hair – that they used to develop a nanotherapy infusion. The nanotherapy specifically targets a certain type of immune cell that penetrates the plaque and becomes part of the plaque. These treated cells “eat away” parts of the plaque core, removing it from the artery wall and reducing the extent of blood vessel inflammation.  Previous… 

more »Nanoparticle infusion works against clogged arteries

FDA Approves New Treatment for Hemophilia A or B

Today, the U.S. Food and Drug Administration approved Hympavzi (marstacimab-hncq) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with hemophilia A without factor VIII inhibitors or hemophilia B without factor IX inhibitors (neutralizing antibodies). Hympavzi is a new type of drug that, rather than replacing a clotting factor, works by reducing the amount, and therefore, the activity of, the naturally occurring anticoagulation protein called tissue factor pathway inhibitor. This increases the amount of thrombin, an enzyme that is critical in blood clotting, that is generated. This is expected to reduce or prevent the frequency of bleeding episodes.

Acute health hazard: Radon contaminates Germany

  • News

Radon represents an underestimated health hazard in Germany. The radioactive noble gas is formed during the decay of uranium in the soil and can accumulate in buildings, where it becomes the second most common cause of lung cancer after smoking[1][2]. Distribution and Exposure The average radon concentration in German homes is about 65 becquerels per cubic meter (Bq/m³)[5]. However, there are significant regional differences: significantly higher values are measured in mountainous regions such as the Black Forest, the Ore Mountains, and the Bavarian Forest. There, concentrations in basements and living areas can reach 1,000-10,000 Bq/m³ or more[3]. According to estimates by the Federal Office for Radiation Protection (BfS), about 10.5 million people in Germany are exposed to radon concentrations of over 100 Bq/m³ in their homes. For just under 2 million people, the values even exceed 300 Bq/m³[5]. Health Effects The risk of developing lung cancer increases linearly with radon concentration and duration of exposure. Per 100 Bq/m³ increase…

more »Acute Health Hazard: Radon Radiates Germany

JRC improves diagnosis of genetic blood diseases

  • News

To support the standardization of blood tests across different laboratories, the JRC develops clinically certified reference materials (CRMs). These control materials form the basis for reliable and stable clinical measurements. A CRM is usually supplied in a "bottle," a sample with a known amount of the substance to be measured, like a gold standard for laboratory tests. When laboratories use these CRMs, they can be sure that their results are correct and precise. The JRC has now released a new CRM to support the fight against beta-thalassemia. This genetic blood disease reduces the production of hemoglobin, the iron-containing protein in red blood cells that transports oxygen throughout the body. It can lead to severe anemia, and patients may require lifelong blood transfusions. In extreme cases, untreated beta-thalassemia can lead to death. The disease occurs worldwide but is more common in Mediterranean countries. In Italy, approximately…

more »JRC improves diagnosis of genetic blood diseases

Defective sperm double the risk of pre-eclampsia

  • News

For the first time, researchers have linked certain common defects in sperm to the risk of pregnancy complications and negative effects on the baby's health. The study from Lund University in Sweden shows that a high proportion of the father's sperm with DNA strand breaks is associated with double the risk of preeclampsia in women who became pregnant through IVF. It also increases the risk of the baby being born prematurely. The findings showed that in the 841 couples undergoing IVF, a DFI of over 20 percent doubled the woman's risk of developing preeclampsia (10.5 percent) and also increased the risk of premature birth. In the IVF group with a DFI below 20 percent, there was a 4.8 percent risk of preeclampsia, comparable to pregnancies conceived naturally. For couples undergoing...

more »Defective sperm double the risk of preeclampsia

FDA Approves New Combination Therapy for Advanced Breast Cancer

  • News

In a significant development for breast cancer treatment, the U.S. Food and Drug Administration (FDA) has approved a new combination therapy for certain types of advanced breast cancer. On October 10, 2024, the FDA gave the green light to inavolisib (brand name Itovebi), manufactured by Genentech, Inc., to be used in combination with palbociclib and fulvestrant[1]. This approval is specifically for adult patients with endocrine-resistant, PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth-factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer[1]. The treatment is indicated for patients whose cancer has recurred after or during adjuvant endocrine therapy, as detected by an FDA-approved test[1]. The approval was based on the results of the INAVO120 trial, which involved 325 patients with the specified type of breast cancer[1]. The study showed significant improvements in progression-free survival for patients receiving the inavolisib combination compared…

more »FDA Approves New Combination Therapy for Advanced Breast Cancer

B. Braun and Fresenius help Baxter

Fresenius Medical Care announced on Thursday that the company will increase its production of IV fluids and peritoneal dialysis (PD) products, as the U.S. faces shortages due to the impact of Hurricane Helene on supply chains. The company is maximizing production capacity at its international sites to improve supply amid an industry-wide shortage of PD products and IV fluids, the update stated. At the request of the Department of Health, Fresenius Medical Care is also exploring other options to address the shortage. https://www.freseniusmedicalcare.com/en/news/ramping-up-supply-of-iv-fluids-and-pd-products-post-hurricane-helene-and-ensuring-safety-of-patients-and-employees-in-the-face-of-hurricane-milton

Predictive Power of the CP-GEP Merlin Test

The Merlin Test  (CP-GEP) Accurately Stratifies Cutaneous Melanoma Patients as Low Risk or High Risk for Sentinel Lymph Node Metastases Impacting Clinical Decision Making Merlin test  (CP-GEP) [1] successfully stratifies T1a melanoma patients considered for sentinel lymph node biopsy (SLNB) by their care providers, reducing SLNB surgeries by 87.6% with a negative predictive value (NPV) of 98.5%.Merlin test  (CP-GEP) identifies high-risk T1a melanoma patients for SLNB surgery, even those who might be missed due to the absence of conventional adverse features, offering a more precise and individualized approach to managing early-stage melanoma.

NIS2 and DORA as Cyberdefense Tools

With the introduction of the NIS2 Directive and the DORA Regulation, a significant change in information security is imminent for European companies. These new regulations aim to considerably strengthen cybersecurity and digital resilience in the EU's internal market. While NIS2 focuses on the protection of critical infrastructures, DORA focuses on securing digital financial systems. Experts estimate that around 150,000 European organizations will be affected by NIS2, which corresponds to a tenfold increase compared to the previous directive NIS1 [2]. These figures illustrate the far-reaching impact of the new regulations on the corporate landscape. The implementation of NIS2 and DORA requires more than just meeting compliance requirements. Companies should use these regulations as an opportunity to fundamentally rethink and optimize their information security strategies. Dr. Jan Scharfenberg, lawyer for Regulatory Compliance, emphasizes the need for a holistic approach: “It is about anchoring information security as an integral part of corporate strategy and not just… 

more »NIS2 and DORA as Cyberdefense Tools

Federal Court of Auditors warns coalition about pension package II

The Federal Court of Auditors is sharply criticizing the federal government's pension package II. “The pension package II will significantly increase the federal government's financial commitment to pension insurance,” states the Court of Auditors' position for the expert hearing in the Bundestag next Monday, as reported by the "Rheinische Post". "The federal subsidies and contributions of the federal government for […] Federal Court of Auditors warns coalition about pension package II